Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices 19563 

Requests should be made at least 7 days 

in advance of the meeting. 

SUPPLEMENTARY INFORMATION: 

Preliminary Agenda Topics and 

Availability of Meeting Materials 

Preliminary agenda topics include: 

• NICEATM–ICCVAM Update. 

• Regulatory Acceptance of ICCVAM– 

Recommended Alternative Test 

Methods. 

• NRC Report Recognition and 

Alleviation of Pain in Laboratory 

Animals. 

• Implementation of NICEATM– 

ICCVAM Five-Year Plan. 

• Federal Agency Research, 

Development, Translation, and 

Validation Activities Relevant to the 

NICEATM–ICCVAM Five-Year Plan 

(EPA and USDA). 

• Report on second meeting of 

Independent Peer Review Panel: 

Evaluation of the Updated Validation 

Status of New Versions and 

Applications of the Murine Local 

Lymph Node Assay: Assessing the 

Allergic Contact Dermatitis Potential of 

Chemicals and Products. 

• Report on the Independent 

Scientific Peer Review Panel on 

Alternative Ocular Safety Testing 

Methods. 

• Update from the Japanese Center for 

the Validation of Alternative Methods. 

• Update from the European Centre 

for the Evaluation of Alternative 

Methods. 

• Update from Health Canada. 

A copy of the preliminary agenda, 

committee roster, and additional 

information, when available, will be 

posted on the NTP Web site (http:// 

ntp.niehs.nih.gov/go/7441) or available 

upon request (see ADDRESSES above). 

Following the SACATM meeting, 

summary minutes will be prepared and 

available on the NTP Web site or upon 

request. 

Request for Comments 

Both written and oral public input on 

the agenda topics is invited. Written 

comments received in response to this 

notice will be posted on the NTP Web 

site. Persons submitting written 

comments should include their name, 

affiliation (if applicable), and 

sponsoring organization (if any) with 

the document. Time is allotted during 

the meeting for presentation of oral 

comments and each organization is 

allowed one time slot per public 

comment period. At least 7 minutes will 

be allotted for each speaker, and if time 

permits, may be extended up to 10 

minutes at the discretion of the chair. 

Registration for oral comments will also 

be available on-site, although time 

allowed for presentation by on-site 

registrants may be less than for preregistered speakers and will be 

determined by the number of persons 

who register at the meeting. 

Persons registering to make oral 

comments are asked to do so through 

the online registration form (http:// 

ntp.niehs.nih.gov/go/7441) and to send 

a copy of their statement to Dr. White 

(see ADDRESSES above) by June 17, 2009, 

to enable review by SACATM, 

NICEATM–ICCVAM, and NIEHS/NTP 

staff prior to the meeting. Written 

statements can supplement and may 

expand the oral presentation. If 

registering on-site and reading from 

written text, please bring 40 copies of 

the statement for distribution and to 

supplement the record. 

Background Information on ICCVAM, 

NICEATM, and SACATM 

ICCVAM is an interagency committee 

composed of representatives from 15 

Federal regulatory and research agencies 

that use, generate, or disseminate 

toxicological information. ICCVAM 

conducts technical evaluations of new, 

revised, and alternative methods with 

regulatory applicability and promotes 

the development, scientific validation, 

regulatory acceptance, implementation, 

and national and international 

harmonization of new, revised, and 

alternative toxicological test methods 

that more accurately assess the safety 

and hazards of chemicals and products 

and that refine, reduce, and replace 

animal use. The ICCVAM Authorization 

Act of 2000 [42 U.S.C. 285l–3] 

established ICCVAM as a permanent 

interagency committee of the NIEHS 

under NICEATM. NICEATM 

administers ICCVAM and provides 

scientific and operational support for 

ICCVAM-related activities. NICEATM 

and ICCVAM work collaboratively to 

evaluate new and improved test 

methods applicable to the needs of U.S. 

Federal agencies. Additional 

information about ICCVAM and 

NICEATM can be found on their Web 

site (http://iccvam.niehs.nih.gov). 

SACATM was established in response 

to the ICCVAM Authorization Act 

[Section 285l–3(d)] and is composed of 

scientists from the public and private 

sectors. SACATM advises ICCVAM, 

NICEATM, and the Director of the 

NIEHS and NTP regarding statutorily 

mandated duties of ICCVAM and 

activities of NICEATM. SACATM 

provides advice on priorities and 

activities related to the development, 

validation, scientific review, regulatory 

acceptance, implementation, and 

national and international 

harmonization of new, revised, and 

alternative toxicological test methods. 

Additional information about SACATM, 

including the charter, roster, and 

records of past meetings, can be found 

at http://ntp.niehs.nih.gov/go/167. 

Dated: April 22, 2009. 

John R. Bucher, 

Associate Director, National Toxicology 

Program. 

[FR Doc. E9–9845 Filed 4–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-09–0128] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 or send 

comments to Maryam Daneshvar, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an e-mail to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Congenital Syphilis (CS) Case 

Investigation and Report Form 

(CDC73.126), OMB No. 0920–0128— 

revision—National Center for HIV/ 

AIDS, Viral Hepatitis, Sexually 

Transmitted Diseases, and Tuberculosis 

Prevention, (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 


pwalker on PROD1PC71 with NOTICES
19564 Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices 

Background and Brief Description 

Reducing congenital syphilis is a 

national objective in the DHHS Report 

entitled ‘‘Healthy People 2010 (Vol. I 

and II)’’. Objective 25–9 of the DHHS 

document states the goal to ‘‘reduce 

congenital syphilis to 1 new case per 

100,000 live births’’. In order to meet 

this national objective, an effective 

surveillance system for congenital 

syphilis must be continued to monitor 

current levels of disease and progress 

towards the year 2010 objective. The 

purpose of the revision is to 

accommodate minor change to the 

‘‘Congenital Syphilis (CS) Case 

Investigation and Report Form’’ 

(CDC73.126). In the proposed revision, 

the ‘‘reporting city’’ and ‘‘resident city’’ 

information blocks in the ‘‘Congenital 

Syphilis (CS) Case Investigation and 

Report’’ data collection form will be 

removed because several states have 

begun to use a 5-digit (rather than 4- 

digit) FIPS code for city, and CDC data 

systems cannot accommodate the new 

codes. 

The congenital syphilis data will 

continue to be used to develop 

intervention strategies and to evaluate 

ongoing control efforts. There is no cost 

to respondents other than their time. 

ESTIMATE OF ANNUALIZED BURDEN TABLE

Type of respondents Name of form No. of 

respondents 

No. of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

State and local health departments .. Congenital Syphilis (CS) Case Investigation and Report.18 11 20/60 66 

Total ........................................... ........................................................... 18 ........................ ........................ 66 

Dated: April 23, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–9772 Filed 4–28–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Strengthening 

National Capacity in Malaria and Other 

Infectious Disease Operations 

Research, Funding Opportunity 

Announcement (FOA) CK09–003 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting. 

Time And Date: 12 p.m.–3 p.m., June 11, 

2009 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of ‘‘Strengthening National 

Capacity in Malaria and Other Infectious 

Disease Operations Research, Funding 

Opportunity Announcement (FOA) CK09– 

003.’’ 

Contact Person For More Information: 

Wendy Carr, PhD, CDC, 1600 Clifton Road, 

NE., Mailstop D60, Atlanta, GA 30333, 

Telephone: (404) 498–2276. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 17, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–9743 Filed 4–28–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel. 

Date: May 5, 2009. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call) 

Contact Person: William C. Benzing, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division Of Extramural 

Research, NINDS/NIH/DHHS/Neuroscience 

Center, 6001 Executive Boulevard, Suite 

3204, MSC 9529, Bethesda, MD 20892, (301) 

496–0660, benzingw@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: April 23, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9863 Filed 4–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

Mental Health Special Emphasis Panel, 

May 14, 2009, 9 a.m. to May 14, 2009, 

5 p.m., Melrose Hotel, 2430 

Pennsylvania Ave., NW., Washington, 

DC 20037 which was published in the 

Federal Register on April 17, 2009, 74 

FR N17874. 

The meeting will be held on June 2, 

2009. The time and meeting location 


pwalker on PROD1PC71 with NOTICES